Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER.
BETAPACE vs ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Selective beta-1 adrenergic receptor antagonist with rapid onset and short duration of action; reduces heart rate, myocardial contractility, and blood pressure; no intrinsic sympathomimetic activity or membrane stabilizing activity.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
Intravenous loading dose: 500 mcg/kg over 1 minute, followed by maintenance infusion: 50 mcg/kg/min for 4 minutes; if adequate response not achieved, repeat loading dose and increase maintenance infusion by 50 mcg/kg/min increments up to 200 mcg/kg/min.
None Documented
None Documented
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
Terminal elimination half-life is approximately 9 minutes (range 6–12 min) in healthy adults; prolonged to 15–20 min in hepatic impairment. Clinical context: rapid offset allows precise titration.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Rapid hydrolysis by esterases in blood and tissues to inactive acid metabolite (ASL-8123) and methanol. Less than 2% excreted unchanged in urine. Renal elimination of metabolite accounts for >80% of dose; <5% fecal.
Category C
Category A/B
Beta-Blocker
Beta-Blocker